NVS  Novartis Ag




Consumer Durables


Major Pharmaceuticals

Market Cap.


Vuru Grade


Current Price

-0.19 (-0.19%)

Growth Price

Overvalued by 35.46%

Stability Price

Overvalued by 77.99%

Company Metrics

  • 11.94 P/E
  • 4.52 P/S
  • 3.12 P/B
  • 8.24 EPS
  • 12.42% Cash ROIC
  • 0.51 Cash Ratio
  • 2.67 / 2.70 % Dividend
  • 1.26M Avg. Vol.
  • 238.02B Market Cap.

Company Description

Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division offers prescription medicines in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; integrated hospital care; and other additional products. The company's Vaccines...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Novartis AG (ADR) (NVS) To Acquire Spinifex For $200 Million
Bidness ETC - Jun 29, 2015
Novartis AG ADR (NYSE:NVS) has agreed to acquire Spinifex Pharmaceuticals, a US-Australian pain management biotech company, to strengthen its position in the pain management market, according to separate statements released by both companies ...
Novartis AG (ADR) (NVS) To Acquire Spinifex - Business Finance News
Novartis to buy privately held Spinifex for $200 mln - Proactive Investors USA & Canada
Novartis AG (ADR) Says Cosentyx Can Be A $5 Billion Drug After New Trial Data
Bidness ETC - Jun 29, 2015
Novartis AG (ADR) (NYSE:NVS) has updated its annual sales forecast for its potential blockbuster injectable drug Cosentyx (secukinumab), after new clinical data establishes the drug's long-term benefits in treating psoriatic arthritis.
Novartis AG (ADR) (NVS) Looks For Performance Based Pricing System Ahead ...
InvestCorrectly - 34 minutes ago
Novartis AG (ADR) (NYSE:NVS) seems to have heard the feelings of a number of people, who were not happy with the higher costs spent towards new drugs.
Stock Report on Novartis AG (ADR) (NYSE:NVS)
Street Report - Jun 16, 2015
[CNW Group] Novartis AG (ADR) (NYSE:NVS)(TREND ANALYSIS) announced one-year study results from the MEASURE 2 pivotal Phase III study of investigational secukinumab in ankylosing spondylitis (AS).
Novartis AG (ADR) Expects Higher Profit Margin & Dividends This Year
Bidness ETC - Jun 19, 2015
Novartis AG (ADR) (NYSE:NVS) expects its profit margin to increase in 2015 on the back of a restructured drug portfolio and cost-cutting measures.
Technical Insights on Novartis AG (ADR) (NYSE:NVS)
Markets Wired - Apr 23, 2015
[Bloomberg] Novartis AG (ADR) (NYSE:NVS)(TREND ANALYSIS) the world's biggest drugmaker by sales, reported first-quarter profit that beat analysts' estimates as the company begins to benefit from a set of transactions that make it smaller and more ...
Novartis AG (ADR) (NVS) Seeks $2-5 Billion Takeover Targets - Bidness ETC
Novartis (NVS) Beats on Earnings in Q1, View Reiterated - Zacks.com
GlaxoSmithKline plc (ADR) (GSK), Novartis AG (ADR) (NVS), Sanofi SA (ADR ...
Bidness ETC - May 7, 2015
The stocks include London-based GlaxoSmithKline plc (ADR) (NYSE:GSK), Switzerland-based Novartis AG (ADR) (NYSE:NVS) and France-based Sanofi SA (ADR) (NYSE:SNY).
GlaxoSmithKline Plc (ADR) (NYSE:GSK) Unveils Big Business Growth Targets - WallStreetPR (blog)
GlaxoSmithKline scraps HIV spinout, reports higher Q1 profit - Proactive Investors USA & Canada
General Report on Novartis AG (ADR) (NYSE:NVS)
Markets Wired - May 28, 2015
[Reuters] Novartis AG (ADR) (NYSE:NVS)(TREND ANALYSIS) Swiss drugmaker Novartis is raising its bet on smart technology by collaborating with U.S.
Novartis AG (ADR) (NYSE:NVS) is All Set to Rule the Immunotherapy Market
WallStreet.org - Jun 10, 2015
Head of Novartis AG (ADR) (NYSE:NVS)'s oncology department Mr. Bill Hinshaw, said in one of his recent webcast briefing that Novartis will be playing an important role in this field and the company is well-positioned to do so.
Teva Pharmaceutical Copaxone Patent Nixed By US Court Again; Novartis AG ...
Bidness ETC - Jun 19, 2015
The US Court of Appeals ruled for the second time on Thursday that Teva Pharmaceutical Industries Ltd.'s (ADR) (NYSE:TEVA) patent for its top-selling multiple sclerosis (MS) drug Copaxone is invalid.